Compare IGIC & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IGIC | PRCT |
|---|---|---|
| Founded | 2001 | 2009 |
| Country | Jordan | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2019 | 2021 |
| Metric | IGIC | PRCT |
|---|---|---|
| Price | $24.72 | $18.00 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 11 |
| Target Price | $28.00 | ★ $35.44 |
| AVG Volume (30 Days) | 60.4K | ★ 1.1M |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | ★ 5.25% | N/A |
| EPS Growth | N/A | ★ 1.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $308,054,000.00 |
| Revenue This Year | $0.13 | $31.34 |
| Revenue Next Year | $2.54 | $24.52 |
| P/E Ratio | $9.05 | ★ N/A |
| Revenue Growth | N/A | ★ 37.22 |
| 52 Week Low | $20.82 | $16.67 |
| 52 Week High | $29.59 | $38.11 |
| Indicator | IGIC | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 37.81 |
| Support Level | N/A | $16.89 |
| Resistance Level | N/A | $29.27 |
| Average True Range (ATR) | 0.00 | 1.04 |
| MACD | 0.00 | -0.30 |
| Stochastic Oscillator | 0.00 | 0.00 |
International General Insurance Holdings Ltd is an international specialty insurance and reinsurance group. It underwrites a diversified portfolio of specialty risks including energy, property, construction and engineering, ports and terminals, general aviation, political violence, professional lines, financial institutions, marine, contingency and treaty reinsurance. The company's operating segments include Specialty Longtail, Specialty Short tail and Reinsurance. The majority of revenue is derived from the Specialty Short-tail segment, which comprises business lines with underwriting risks assumed in the form of property and specialty lines insurance and of short-term nature with respect to related claims.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.